サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1764312

家族性アミロイドポリニューロパシーの世界市場レポート 2025年

Familial Amyloid Polyneuropathy Global Market Report 2025

出版日
ページ情報
英文 175 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.66円
家族性アミロイドポリニューロパシーの世界市場レポート 2025年
出版日: 2025年07月07日
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

家族性アミロイドポリニューロパシー市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.1％で22億5,000万米ドルに成長します。予測期間中に予想される成長の要因としては、希少疾患治療に特化した政府の取り組みや資金提供の拡大、革新的な治療法を検査する臨床検査の増加、治療法改善への需要を煽る患者擁護・支援団体の増加、新興市場におけるヘルスケアインフラへのアクセス強化、高度診断技術の利用可能性の拡大などが挙げられます。この期間に予想される主要動向には、遺伝子配列決定技術の進歩、個別化医療の採用、バイオマーカー同定技術の進歩、ドラッグデリバリーシステムの改善、デジタルヘルスツールと遠隔医療の導入などがあります。

遺伝子治療への注目の高まりが、今後の家族性アミロイドポリニューロパシー市場の成長を牽引すると予想されます。遺伝子治療は、病気の根本的な原因を治療するために、欠陥のある遺伝子を修正または置換することを含みます。このアプローチは、欠陥のある遺伝子を対象にして修復するため、単に症状を緩和するだけでなく、永続的または恒久的な治療法を提供できる可能性があり、支持を集めています。家族性アミロイドポリニューロパシーでは、遺伝子治療は、有害なアミロイドタンパク質の蓄積を防ぐために、変異したトランスサイレチン（TTR）遺伝子を修正または沈黙させることを目的としています。これにより、アミロイドの沈着が減少し、病気の進行が遅くなり、神経機能の維持に役立ちます。例えば、2023年7月、米国を拠点とする専門組織である米国遺伝子・細胞治療学会（ASGCT）と、米国を拠点とする医薬品・機器プロバイダであるCitelineは、第II相臨床検査中の遺伝子治療の数が、2023年第1四半期末の247件から、第2四半期末には260件と5％増加したと報告しました。このように、遺伝子治療への注目の高まりが家族性アミロイドポリニューロパシー市場の拡大に拍車をかけています。

家族性アミロイドポリニューロパシー市場の主要企業は、RNA干渉（RNAi）治療など、疾患の進行を遅らせ、患者の予後を改善するための市場の開拓に注力しています。RNAi治療は、疾患の原因となる遺伝子のメッセンジャーRNA（mRNA）を標的とすることにより、その遺伝子をサイレンシングし、有害なタンパク質の産生を阻止し、遺伝性疾患の根源から対処します。例えば、米国を拠点とするバイオ医薬品会社アルナイラム・ファーマシューティカルズは2025年3月、成人の野生型または遺伝性トランスサイレチン介在性アミロイドーシス（ATTR-CM）による心筋症の治療としてFDAの承認を取得したAMVUTTRA（ブトリシラン）を発売しました。本療法は年4回の皮下投与で、ATTR-CMと遺伝性トランスサイレチン介在性アミロイドーシスポリニューロパチー（hATTR-PN）の両方を治療するようにデザインされています。HELIOS-B第3相臨床検査で証明されたように、この疾患の根本原因であるトランスサイレチン（TTR）タンパクの産生を減少させることにより、心血管系死亡率、入院、心不全の緊急受診を有意に減少させています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、コロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界の家族性アミロイドポリニューロパシー：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
  • 最終用途産業の分析
  • 世界の家族性アミロイドポリニューロパシー市場：成長率分析
  • 世界の家族性アミロイドポリニューロパシー市場の実績：規模と成長、2019～2024年
  • 世界の家族性アミロイドポリニューロパシー市場の予測：規模と成長、2024～2029年、2034年
  • 世界の家族性アミロイドポリニューロパシー：総潜在市場規模（TAM）

第6章 市場セグメンテーション

  • 世界の家族性アミロイドポリニューロパシー市場：治療別、実績と予測、2019～2024年、2024～2029年、2034年
  • 医薬品
  • 遺伝子治療
  • 支持療法
  • 疼痛管理
  • 治療
  • 世界の家族性アミロイドポリニューロパシー市場：診断別、実績と予測、2019～2024年、2024～2029年、2034年
  • 遺伝子検査
  • 生検
  • 画像診断
  • その他
  • 世界の家族性アミロイドポリニューロパシー市場：患者年齢層別、実績と予測、2019～2024年、2024～2029年、2034年
  • 小児
  • 成人
  • 高齢者
  • 世界の家族性アミロイドポリニューロパシー市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
  • 病院薬局
  • 小売薬局
  • オンライン薬局
  • 専門薬局
  • 直接販売
  • 世界の家族性アミロイドポリニューロパシー市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
  • 病院
  • 専門クリニック
  • 研究機関
  • その他
  • 世界の家族性アミロイドポリニューロパシー市場、医薬品のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • トランスサイレチン（TTR）安定剤
  • トランスサイレチン（TTR）遺伝子サイレンサー
  • タファミディス
  • ジフルニサル
  • パティシラン
  • 世界の家族性アミロイドポリニューロパシー市場、遺伝子治療のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • CRISPR（Clustered Regularly Interspaced Short Palindromic Repeat）またはCas9ベースの治療法
  • RNA干渉（RNAi）療法
  • アンチセンスオリゴヌクレオチド（ASO）療法
  • 世界の家族性アミロイドポリニューロパシー市場、支持療法のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 理学療法
  • 作業療法
  • 栄養サポート
  • 心理カウンセリング
  • 世界の家族性アミロイドポリニューロパシー市場、疼痛管理のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 非ステロイド性抗炎症薬（NSAID）
  • オピオイド
  • 抗うつ薬
  • 抗けいれん薬
  • 世界の家族性アミロイドポリニューロパシー市場、治療のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 胃腸症状の管理
  • 心血管症状の管理
  • 自律神経機能障害の管理
  • 起立性低血圧の治療

第7章 地域別・国別分析

  • 世界の家族性アミロイドポリニューロパシー市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
  • 世界の家族性アミロイドポリニューロパシー市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 家族性アミロイドポリニューロパシー市場：競合情勢
  • 家族性アミロイドポリニューロパシー市場：企業プロファイル
    • Pfizer Inc.
    • AstraZeneca plc
    • Novo Nordisk A/S
    • Regeneron Pharmaceuticals Inc.
    • NYU Langone Hospitals

第31章 その他の大手企業と革新的企業

  • Alexion Pharmaceuticals Inc.
  • Alnylam Pharmaceuticals Inc.
  • Mount Sinai Medical Center
  • PTC Therapeutics Inc.
  • Ionis Pharmaceuticals Inc.
  • Mayo Foundation for Medical Education and Research
  • Arcturus Therapeutics Inc.
  • Prothena Corporation plc
  • Precision BioSciences Inc.
  • Intellia Therapeutics Inc.
  • Creative Biolabs
  • Stanford Health Care
  • Attralus Inc.
  • Duke University Health System
  • YolTech Therapeutics

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

  • 家族性アミロイドポリニューロパシー市場、2029年：新たな機会を提供する国
  • 家族性アミロイドポリニューロパシー市場、2029年：新たな機会を提供するセグメント
  • 家族性アミロイドポリニューロパシー市場、2029年：成長戦略
    • 市場動向による戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r35900

Familial amyloid polyneuropathy (FAP) is a rare inherited disorder caused by mutations in the transthyretin (TTR) gene, leading to the buildup of amyloid proteins in peripheral nerves and vital organs. This progressive condition primarily affects the nervous system, causing sensory, motor, and autonomic impairments. Early diagnosis and proper management focus on slowing disease progression, easing symptoms, and improving the patient's quality of life.

The main treatment options for familial amyloid polyneuropathy include medication, gene therapy, supportive care, pain management, and symptomatic relief. Medications help by slowing the disease's advancement, reducing symptoms, and enhancing patients' quality of life. Diagnosis can be performed using various techniques such as genetic testing, biopsy, imaging, and others, across different age groups including pediatric, adult, and geriatric patients. Treatments are distributed through multiple channels like hospital pharmacies, retail and online pharmacies, specialty pharmacies, and direct sales, and are utilized by various end-users including hospitals, specialty clinics, research institutes, and more.

The familial amyloid polyneuropathy market research report is one of a series of new reports from The Business Research Company that provides familial amyloid polyneuropathy market statistics, including the familial amyloid polyneuropathy industry global market size, regional shares, competitors with the familial amyloid polyneuropathy market share, detailed familial amyloid polyneuropathy market segments, market trends, opportunities, and any further data you may need to thrive in the familial amyloid polyneuropathy industry. This familial amyloid polyneuropathy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The familial amyloid polyneuropathy market size has grown strongly in recent years. It will grow from $1.52 billion in 2024 to $1.65 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The growth during the historic period can be attributed to the rising prevalence of familial amyloid polyneuropathy, improved awareness and diagnosis rates driven by advances in genetic testing, increased adoption of new therapeutic and targeted treatment options, greater investment in research and development for amyloidosis therapies, and a growing elderly population vulnerable to amyloid-related neuropathies.

The familial amyloid polyneuropathy market size is expected to see strong growth in the next few years. It will grow to $2.25 billion in 2029 at a compound annual growth rate (CAGR) of 8.1%. The growth expected during the forecast period can be attributed to expanding government initiatives and funding dedicated to rare disease treatments, a rising number of clinical trials testing innovative therapies, increased patient advocacy and support groups fueling demand for improved treatments, enhanced access to healthcare infrastructure in emerging markets, and greater availability of advanced diagnostic technologies. Key trends anticipated in this period include progress in genetic sequencing technologies, the adoption of personalized medicine, advancements in biomarker identification techniques, improvements in drug delivery systems, and the incorporation of digital health tools and telemedicine.

The increasing emphasis on gene therapy is expected to drive the growth of the familial amyloid polyneuropathy market going forward. Gene therapy involves modifying or replacing faulty genes to treat the root cause of diseases. This approach is gaining traction because it targets and repairs defective genes, potentially providing lasting or permanent cures rather than just alleviating symptoms. For familial amyloid polyneuropathy, gene therapy aims to correct or silence the mutated transthyretin (TTR) gene to prevent the buildup of harmful amyloid proteins. This reduces amyloid deposits, slows disease progression, and helps preserve nerve function. For example, in July 2023, the American Society of Gene & Cell Therapy (ASGCT), a U.S.-based professional organization, and Citeline, a U.S.-based drug and device provider, reported that the number of gene therapies in Phase II clinical trials increased from 247 at the end of the first quarter of 2023 to 260 by the end of the second quarter, a 5% rise. Thus, the growing focus on gene therapy is fueling the expansion of the familial amyloid polyneuropathy market.

Leading companies in the familial amyloid polyneuropathy market are concentrating on developing advanced therapies such as RNA interference (RNAi) treatments to slow disease progression and enhance patient outcomes. RNAi therapeutics work by silencing disease-causing genes through targeting their messenger RNA (mRNA), thereby preventing the production of harmful proteins and addressing genetic disorders at their source. For example, in March 2025, Alnylam Pharmaceuticals, a U.S.-based biopharmaceutical firm, launched AMVUTTRA (vutrisiran), which received FDA approval for the treatment of cardiomyopathy caused by wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. The therapy is administered as four subcutaneous doses annually and is designed to treat both ATTR-CM and hereditary transthyretin-mediated amyloidosis polyneuropathy (hATTR-PN). By reducing transthyretin (TTR) protein production-the underlying cause of the disease-it significantly decreases cardiovascular mortality, hospitalizations, and urgent heart failure visits, as evidenced in the HELIOS-B Phase 3 clinical trial.

In March 2023, Alnylam Pharmaceuticals, a U.S.-based developer of RNAi therapies for hereditary transthyretin-mediated amyloidosis, formed a partnership with Medison Pharma to expand global access to innovative RNAi treatments. The collaboration seeks to speed up and widen patient availability of Alnylam's RNAi therapeutics for rare and serious diseases by utilizing Medison Pharma's integrated commercialization platform across multiple international markets. Medison Pharma is a pharmaceutical company headquartered in Israel.

Major players in the familial amyloid polyneuropathy market are Pfizer Inc., AstraZeneca plc, Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., NYU Langone Hospitals, Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Mount Sinai Medical Center, PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Mayo Foundation for Medical Education and Research, Arcturus Therapeutics Inc., Prothena Corporation plc, Precision BioSciences Inc., Intellia Therapeutics Inc., Creative Biolabs, Stanford Health Care, Attralus Inc., Duke University Health System, and YolTech Therapeutics.

North America was the largest region in the familial amyloid polyneuropathy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in familial amyloid polyneuropathy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the familial amyloid polyneuropathy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The familial amyloid polyneuropathy market consists of revenues earned by entities providing services such as disease monitoring, patient support and education, neurological assessment, and genetic counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The familial amyloid polyneuropathy market also includes sales of transthyretin stabilizers, diagnostic kits, and monitoring equipment. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Familial Amyloid Polyneuropathy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on familial amyloid polyneuropathy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for familial amyloid polyneuropathy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The familial amyloid polyneuropathy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Treatment: Medication; Gene Therapy; Supportive Care; Pain Management; Symptomatic Treatment
  • 2) By Diagnosis: Genetic Testing; Biopsy; Imaging; Other Diagnosis
  • 3) By Patient Age Group: Pediatric; Adult; Geriatric
  • 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Specialty Pharmacies; Direct Sales
  • 5) By End-User: Hospitals; Specialty Clinics; Research Institutes; Other End-Users
  • Subsegments:
  • 1) By Medication: Transthyretin (TTR) Stabilizers; Transthyretin (TTR) Gene Silencers; Tafamidis; Diflunisal; Patisiran
  • 2) By Gene Therapy: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or Cas9-Based Therapy; RNA Interference (RNAi) Therapy; Antisense Oligonucleotides (ASO) Therapy
  • 3) By Supportive Care: Physical Therapy; Occupational Therapy; Nutritional Support; Psychological Counseling
  • 4) By Pain Management: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs); Opioids; Antidepressants; Anticonvulsants
  • 5) By Symptomatic Treatment: Gastrointestinal Symptom Management; Cardiovascular Symptom Management; Autonomic Dysfunction Management; Orthostatic Hypotension Treatment
  • Companies Mentioned: Pfizer Inc.; AstraZeneca plc; Novo Nordisk A/S; Regeneron Pharmaceuticals Inc.; NYU Langone Hospitals
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Familial Amyloid Polyneuropathy Market Characteristics

3. Familial Amyloid Polyneuropathy Market Trends And Strategies

4. Familial Amyloid Polyneuropathy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Familial Amyloid Polyneuropathy Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Familial Amyloid Polyneuropathy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Familial Amyloid Polyneuropathy Market Growth Rate Analysis
  • 5.4. Global Familial Amyloid Polyneuropathy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Familial Amyloid Polyneuropathy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Familial Amyloid Polyneuropathy Total Addressable Market (TAM)

6. Familial Amyloid Polyneuropathy Market Segmentation

  • 6.1. Global Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Medication
  • Gene Therapy
  • Supportive Care
  • Pain Management
  • Symptomatic Treatment
  • 6.2. Global Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Genetic Testing
  • Biopsy
  • Imaging
  • Other Diagnosis
  • 6.3. Global Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Pediatric
  • Adult
  • Geriatric
  • 6.4. Global Familial Amyloid Polyneuropathy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Specialty Pharmacies
  • Direct Sales
  • 6.5. Global Familial Amyloid Polyneuropathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Specialty Clinics
  • Research Institutes
  • Other End-Users
  • 6.6. Global Familial Amyloid Polyneuropathy Market, Sub-Segmentation Of Medication, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Transthyretin (TTR) Stabilizers
  • Transthyretin (TTR) Gene Silencers
  • Tafamidis
  • Diflunisal
  • Patisiran
  • 6.7. Global Familial Amyloid Polyneuropathy Market, Sub-Segmentation Of Gene Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or Cas9-Based Therapy
  • RNA Interference (RNAi) Therapy
  • Antisense Oligonucleotides (ASO) Therapy
  • 6.8. Global Familial Amyloid Polyneuropathy Market, Sub-Segmentation Of Supportive Care, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Physical Therapy
  • Occupational Therapy
  • Nutritional Support
  • Psychological Counseling
  • 6.9. Global Familial Amyloid Polyneuropathy Market, Sub-Segmentation Of Pain Management, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
  • Opioids
  • Antidepressants
  • Anticonvulsants
  • 6.10. Global Familial Amyloid Polyneuropathy Market, Sub-Segmentation Of Symptomatic Treatment, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Gastrointestinal Symptom Management
  • Cardiovascular Symptom Management
  • Autonomic Dysfunction Management
  • Orthostatic Hypotension Treatment

7. Familial Amyloid Polyneuropathy Market Regional And Country Analysis

  • 7.1. Global Familial Amyloid Polyneuropathy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Familial Amyloid Polyneuropathy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Familial Amyloid Polyneuropathy Market

  • 8.1. Asia-Pacific Familial Amyloid Polyneuropathy Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Familial Amyloid Polyneuropathy Market

  • 9.1. China Familial Amyloid Polyneuropathy Market Overview
  • 9.2. China Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Familial Amyloid Polyneuropathy Market

  • 10.1. India Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Familial Amyloid Polyneuropathy Market

  • 11.1. Japan Familial Amyloid Polyneuropathy Market Overview
  • 11.2. Japan Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Familial Amyloid Polyneuropathy Market

  • 12.1. Australia Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Familial Amyloid Polyneuropathy Market

  • 13.1. Indonesia Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Familial Amyloid Polyneuropathy Market

  • 14.1. South Korea Familial Amyloid Polyneuropathy Market Overview
  • 14.2. South Korea Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Familial Amyloid Polyneuropathy Market

  • 15.1. Western Europe Familial Amyloid Polyneuropathy Market Overview
  • 15.2. Western Europe Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Familial Amyloid Polyneuropathy Market

  • 16.1. UK Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Familial Amyloid Polyneuropathy Market

  • 17.1. Germany Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Familial Amyloid Polyneuropathy Market

  • 18.1. France Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Familial Amyloid Polyneuropathy Market

  • 19.1. Italy Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Familial Amyloid Polyneuropathy Market

  • 20.1. Spain Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Familial Amyloid Polyneuropathy Market

  • 21.1. Eastern Europe Familial Amyloid Polyneuropathy Market Overview
  • 21.2. Eastern Europe Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Familial Amyloid Polyneuropathy Market

  • 22.1. Russia Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Familial Amyloid Polyneuropathy Market

  • 23.1. North America Familial Amyloid Polyneuropathy Market Overview
  • 23.2. North America Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Familial Amyloid Polyneuropathy Market

  • 24.1. USA Familial Amyloid Polyneuropathy Market Overview
  • 24.2. USA Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Familial Amyloid Polyneuropathy Market

  • 25.1. Canada Familial Amyloid Polyneuropathy Market Overview
  • 25.2. Canada Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Familial Amyloid Polyneuropathy Market

  • 26.1. South America Familial Amyloid Polyneuropathy Market Overview
  • 26.2. South America Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Familial Amyloid Polyneuropathy Market

  • 27.1. Brazil Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Familial Amyloid Polyneuropathy Market

  • 28.1. Middle East Familial Amyloid Polyneuropathy Market Overview
  • 28.2. Middle East Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Familial Amyloid Polyneuropathy Market

  • 29.1. Africa Familial Amyloid Polyneuropathy Market Overview
  • 29.2. Africa Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Familial Amyloid Polyneuropathy Market Competitive Landscape And Company Profiles

  • 30.1. Familial Amyloid Polyneuropathy Market Competitive Landscape
  • 30.2. Familial Amyloid Polyneuropathy Market Company Profiles
    • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Novo Nordisk A/S Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Regeneron Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. NYU Langone Hospitals Overview, Products and Services, Strategy and Financial Analysis

31. Familial Amyloid Polyneuropathy Market Other Major And Innovative Companies

  • 31.1. Alexion Pharmaceuticals Inc.
  • 31.2. Alnylam Pharmaceuticals Inc.
  • 31.3. Mount Sinai Medical Center
  • 31.4. PTC Therapeutics Inc.
  • 31.5. Ionis Pharmaceuticals Inc.
  • 31.6. Mayo Foundation for Medical Education and Research
  • 31.7. Arcturus Therapeutics Inc.
  • 31.8. Prothena Corporation plc
  • 31.9. Precision BioSciences Inc.
  • 31.10. Intellia Therapeutics Inc.
  • 31.11. Creative Biolabs
  • 31.12. Stanford Health Care
  • 31.13. Attralus Inc.
  • 31.14. Duke University Health System
  • 31.15. YolTech Therapeutics

32. Global Familial Amyloid Polyneuropathy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Familial Amyloid Polyneuropathy Market

34. Recent Developments In The Familial Amyloid Polyneuropathy Market

35. Familial Amyloid Polyneuropathy Market High Potential Countries, Segments and Strategies

  • 35.1 Familial Amyloid Polyneuropathy Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Familial Amyloid Polyneuropathy Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Familial Amyloid Polyneuropathy Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer